A retrospective study assessing the real-world data of clinical benefit and survival with TAS-102 therapy
Latest Information Update: 24 Dec 2019
Price :
$35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 Dec 2019 New trial record